Antenatal corticosteroids and outcomes of preterm small-for-gestational-age neonates in a single medical center
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective This study investigated the effect of an antenatal corticosteroid (ACS) in preterm small-for-gestational-age (SGA) neonate. Methods This study was a retrospective cohort study. We compared women who received ACS with unexposed controls and evaluated neonatal complications among those having a singleton SGA neonate born between 29 and 34 complete gestational weeks. The neonates born after 32 weeks of gestation were divided into subgroups. Multivariable logistic regression analysis was performed. Results A total 82 of the preterm infants met inclusion criteria; 57 (69.5%) were born after 32 weeks of gestation. There were no significantdifferences in terms of mechanical ventilation, seizure, intracranial hemorrhage, retinopathy of prematurity, necrotizing enterocolitis, feeding difficulty, and neonatal mortality between infants whose mothers received ACS ant those whose mothers did not (all P>0.05). However, newborns whose mothers received ACS exhibited a significantly increased risk of developing respiratory distress syndrome (RDS) (adjusted odds ratio [aOR], 3.271; 95% confidence interval[CI], 1.038-10.305; P=0.043). In case of neonates born beyond 32 weeks of gestation, the risk of neonatal hypoglycemiawas significantly higher in women receiving ACS after controlling for confounding factors (aOR, 5.832; 95% CI, 1.096-31.031; P=0.039). Conclusion ACS did not improve neonatal morbidities, in SGA neonates delivered between 29 and 34 gestational weeks. Rather, ACS could increase the risk of RDS. In cases of SGA neonate delivered between 32 and 34 complete gestational weeks, the risk of hypoglycemia was significantly increased. The use of ACS in women with preterm SGA infants needs to be evaluated further, especially after 32 weeks’ gestation.
Abstract
Objective This study investigated the effect of an antenatal corticosteroid (ACS) in preterm small-for-gestational-age (SGA) neonate. Methods This study was a retrospective cohort study. We compared women who received ACS with unexposed controls and evaluated neonatal complications among those having a singleton SGA neonate born between 29 and 34 complete gestational weeks. The neonates born after 32 weeks of gestation were divided into subgroups. Multivariable logistic regression analysis was performed. Results A total 82 of the preterm infants met inclusion criteria; 57 (69.5%) were born after 32 weeks of gestation. There were no significantdifferences in terms of mechanical ventilation, seizure, intracranial hemorrhage, retinopathy of prematurity, necrotizing enterocolitis, feeding difficulty, and neonatal mortality between infants whose mothers received ACS ant those whose mothers did not (all P>0.05). However, newborns whose mothers received ACS exhibited a significantly increased risk of developing respiratory distress syndrome (RDS) (adjusted odds ratio [aOR], 3.271; 95% confidence interval[CI], 1.038-10.305; P=0.043). In case of neonates born beyond 32 weeks of gestation, the risk of neonatal hypoglycemiawas significantly higher in women receiving ACS after controlling for confounding factors (aOR, 5.832; 95% CI, 1.096-31.031; P=0.039). Conclusion ACS did not improve neonatal morbidities, in SGA neonates delivered between 29 and 34 gestational weeks. Rather, ACS could increase the risk of RDS. In cases of SGA neonate delivered between 32 and 34 complete gestational weeks, the risk of hypoglycemia was significantly increased. The use of ACS in women with preterm SGA infants needs to be evaluated further, especially after 32 weeks’ gestation.
참고문헌 (21)
- "Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes", JAMA, 273, pp.413~418 (1995)[DOI]
- Gyamfi-Bannerman C, "Antenatal betamethasone for women at risk for late preterm delivery", N Engl J Med, 374, pp.1311~1320 (2016)[DOI]
- American College of Obstetricians, "Committee opinion no.677: antenatal corticosteroid therapy for fetal maturation", Obstet Gynecol, 128, pp.e187~e194 (2016)[DOI]
- Liggins GC, "A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants", Pediatrics, 50, pp.515~525 (1972)
- Amiya RM, "Antenatal corticosteroids for reducing adverse maternal and child outcomes in special populations of women at risk of imminent preterm birth: a systematic review and meta-analysis", PLoS One, 11, pp.e0147604~ (2016)[DOI]
- Vidaeff AC, "Potential risks and benefits of antenatal corticosteroid therapy prior to preterm birth in pregnancies complicated by severe fetal growth restriction", Obstet Gynecol Clin North Am, 38, pp.205~214 (2011)[DOI]
- Snyder JM, "Pulmonary development: transition from intrauterine to extrauterine life", pp.19~46 (1985), Marcel Dekker
- 이진경, "Percentile Distributions of Birth Weight according to Gestational Ages in Korea (2010-2012)", Journal of Korean Medical Science, 31(6), pp.939~949 (2016), 대한의학회
- Miller SL, "The effects of maternal betamethasone administration on the intrauterine growth-restricted fetus", Endocrinology, 148, pp.1288~1295 (2007)[DOI]
- Gluckman PD, "Living with the past: evolution, development, and patterns of disease", Science, 305, pp.1733~1736 (2004)[DOI]
- Lillycrop KA, "Epigenetic changes in early life and future risk of obesity", Int J Obes (Lond), 35, pp.72~83 (2011)[DOI]
- Alexander N, "Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children", J Clin Endocrinol Metab, 97, pp.3538~3544 (2012)[DOI]
- Murphy KE, "Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial", Lancet, 372, pp.2143~2151 (2008)[DOI]
- Asztalos E, "Association between gestational age at birth, antenatal corticosteroids, and outcomes at 5 years: multiple courses of antenatal corticosteroids for preterm birth study at 5 years of age (MACS-5)", BMC Pregnancy Childbirth, 14, pp.272~ (2014)[DOI]
- Sotiriadis A, "Neurodevelopmental outcome after a single course of antenatal steroids in children born preterm: a systematic review and meta-analysis", Obstet Gynecol, 125, pp.1385~1396 (2015)[DOI]
- Simchen MJ, "The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction", Am J Obstet Gynecol, 190, pp.296~304 (2004)[DOI]
- Robertson MC, "Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus", Obstet Gynecol, 113, pp.636~640 (2009)[DOI]
- Malaeb SN, "Steroids and injury to the developing brain: net harm or net benefit?", Clin Perinatol, 41, pp.191~208 (2014)[DOI]
- Riskin-Mashiah S, "Antenatal corticosteroid treatment in singleton, small-for-gestational-age infants born at 24-31 weeks' gestation: a population-based study", BJOG, 123, pp.1779~1786 (2016)[DOI]
- Melamed N, "Antenatal corticosteroids and outcomes of small-for-gestational-age neonates", Obstet Gynecol, 128, pp.1001~1008 (2016)[DOI]
- Ishikawa H, "The effects of antenatal corticosteroids on short- and long-term outcomes in small-for-gestational-age infants", Int J Med Sci, 12, pp.295~300 (2015)[DOI]